Clinical Trial Update: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment [Phase 2]

View source ↗

Summary

This update summarizes a Phase 2 trial of zanubrutinib (BGB-3111) in participants with previously treated B-cell lymphomas intolerant to prior BTK inhibitors; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Zanubrutinib (Brukinsa) (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED